How biotech and pharma companies pay their CEOs, and their workers

Chief executives of drugmakers large and small received hefty pay increases over the past two years, shaking off persistent public criticism of the industry to capitalize on strong stock market performance.

Compared to high drug prices, rising executive compensation at biotechnology and pharmaceutical companies has passed without as much scrutiny, even as CEOs benefit handsomely from the sector's steady growth.